New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Acambis Inc.
Division of Sanofi
www.acambis.com
Latest From Acambis Inc.
Emergent Broadens Bioterror Offering In $125m Sanofi Smallpox Vaccine Buy
Sanofi's divestment of its ACAM200 smallpox vaccine frees it to focus on "current and emerging" infectious disease jabs - while expanding Emergent BioSolutions adds to its anti-bioterror product offering.
Flu Speed Ahead in Vaccines Market
Large investments by GlaxoSmithKline and Novartis in the US flu vaccine business highlight a rush back into the business. Government subsidies, technical assistance and market creation are making the flu vaccine field an attractive section of the pharma field again. It has been generally viewed for decades as a risky, difficult buisness with very little growth potential. Now the tables have turned.
VaxInnate Inc.
VaxInnate is linking the innate and adaptive immune response to get the optimal action from a vaccine. Work done in the Yale labs of company founders demonstrated that fusing a polypeptide ligand specific for a TLR to an antigen of interest generates a vaccine that may prove more potent and selective than the antigen alone. It also eliminates the need for formulating the vaccine in complex adjuvants-and it opens the door to production using simplified recombinant methods.
Nasdaq's Siberia
Delisting is the financial equivalent of Siberian exile. And for the past six months, health care's small- cap stocks have been the target of an active purge.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Gastrointestinal
- Infectious & Viral Diseases
- Alias(es)
- OraVax Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Sanofi
- Senior Management
- Gordon Cameron, Pres.
- Contact Info
-
Acambis Inc.
Phone: (617) 494-1339
38 Sidney Street
4th Floor
Cambridge, MA 02139-4169
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acambis Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice